Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)

1.21
Delayed Data
As of Aug 28
 +0.15 / +14.15%
Today’s Change
0.84
Today|||52-Week Range
8.23
-52.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$91.3M

Company Description

Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company primarily engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company's primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis Pharmaceuticals was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Contact Information

Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
South San Francisco California 94080
P:(650) 266-3500
Investor Relations:
(650) 266-3717

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Daniel N. SwisherPresident, Chief Executive Officer & Director
Eric H. BjerkholtCFO, Secretary & EVP-Corporate Development
Gene C. JamiesonVice President-Technical Operations
Adam R. CraigChief Medical Officer & Executive VP-Development
Joseph I. DePintoChief Commercial Officer & Executive VP